#2793
A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction:
High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Weber M
Authors:
Fottner C,
Apostolidis L,
Ferrata M,
Krug S,
Michl P,
Keywords:
NEC,
NEN G3,
check-point inhibitor,
Avelumab,
anti-PD-L1-antibody,
immunotherapy,